Presenting at CMSC 2022, researchers investigated the effects of weight training on bone density, quality of life, and cognition in patients with MS.

Presenting at CMSC 2022, researchers examined the use of powered exoskeletons for gait training, assessing practicality, safety, and clinical outcomes in patients with MS.

A case study presented at the 2022 CMSC Annual Meeting reviews a 47-year-old male patient who experienced relapsing steroid-responsive encephalomyelitis after SARS-CoV-2 infection and subsequent COVID-19 infection.

Presenting at CMSC 2022, researchers assessed the risk for reproductive and embryofetal toxicity in women exposed to ponesimod during pregnancy.

Presenting at CMSC 2022, researchers assessed dimethyl fumarate outcomes among young adult patients with MS who participated in the open-label EVOLVE-MS-1 study.

Presenting at CMSC 2022, researchers evaluated treatment outcomes among patients with MS spasticity being treated with nabiximols with or without such ASMs as baclofen.

Presenting at CMSC 2022, researchers evaluated the relationship between attack severity with serum (s) GFAP and sNfL, and the effect of inebilizumab on attack severity and serum biomarkers.

Researchers sought to characterize health care utilization and identify and describe prodromal symptoms in patients with POMS.

Using the Symbol Digit Modalities Test, researchers evaluated changes in cognitive processing speed among patients with highly active RMS.

Presenting at CMSC 2022, researchers compared switch treatment patterns and therapy selection decisions between DMTs with anti-CD20 mechanism of action.

Presenting at CMSC 2022, researchers described the progression of fatigue in patients with multiple sclerosis.

Presenting at CMSC 2022, researchers assessed the safety and efficacy of DMF for RRMS using real-world data.

Presenting at CMSC 2022, researchers evaluated COVID-19 outcomes among patients with MS who received treatment with ofatumumab.

Researchers sought to determine whether patients who discontinued treatment with ponesimod had an increased risk for MS disease activity exacerbation.

Presenting at CMSC 2022, researchers evaluated the response to the mRNA-1273 vaccine in patients who received DMTs for MS.

Presenting at CMSC 2022, researchers evaluated whether racial patterns exist in NMOSD- and MOGAD-associated ON and the potential role of social disadvantage in these patterns.

Presenting at CMSC 2022, researchers observed how ECG patterns relate to different demographic, clinical, and patient-specific characteristics in patients with MS.

Presenting at CMSC 2022, researchers obtained real-world data on the efficacy and safety of oral cladribine in patients with relapsing-remitting multiple sclerosis.

In a quantitative study, researchers assessed the efficacy of TMS on depressive symptoms in people with MS.

Presenting at CMSC 2022, researchers evaluated the prognostic value of baseline NfL for predicting clinical relapse and change in MRI lesion activity among patients with MS.

Presenting at CMSC 2022, researchers analyzed the development of whole-brain atrophy and white matter lesions in patients with CDMS.

Presenting at CMSC 2022, researchers evaluated the decline in the anti-JCV antibody index in patients with MS through 2 years of ocrelizumab treatment.

Presenting at CMSC 2022, researchers sought to explain the relationship between RLS and quality of life, MS-related disability, and perception of level of disability in patients with MS.